Related references
Note: Only part of the references are listed.Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study
W. Yacoub et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases
Bella Ungar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases
Erwin Dreesen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months
Nicolas Williet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Development and validation of receptor occupancy pharmacodynamic assays used in the clinical development of the monoclonal antibody vedolizumab
Tim Wyant et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis
Andres J. Yarur et al.
INFLAMMATORY BOWEL DISEASES (2016)
Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
M. Rosario et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
Johannan F. Brandse et al.
GASTROENTEROLOGY (2015)
Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases
Andres J. Yarur et al.
INFLAMMATORY BOWEL DISEASES (2015)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum
Shui-Long Wang et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2012)
Inflammatory Bowel Disease Is Associated With an Increased Incidence of Cardiovascular Events
Andres J. Yarur et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis
James D. Lewis et al.
INFLAMMATORY BOWEL DISEASES (2008)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
M Daperno et al.
GASTROINTESTINAL ENDOSCOPY (2004)
Share Paper
